The MOMENTUM Study Evaluating Radiation Therapy Outcomes Using the MR-Linac System in Adult Cancer Patients

What this Trial Is About

Researchers are evaluating the use of the Unity MR-Linac technology in cancer treatment through the Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study MOMENTUM. This international, multi-institutional registry aims to support evidence-based use and further technical development of MR-guided radiation therapy MRGRT to improve survival, tumor control, and quality of life for cancer patients aged 18 and older. The study observes patients receiving treatment and imaging with the MR-Linac, a device combining a linear accelerator with a 1.5 Tesla MRI and adaptive workflow, allowing precise radiation delivery under real-time MRI guidance. Data collected includes technical information from MR-Linac scans during routine care and research, alongside clinical data covering demographics, disease details, treatment, toxicities, cancer outcomes, and patient-reported quality of life. Participants undergo standard MR-Linac radiation therapy and imaging as part of their care. Researchers track progression-free, disease-free, and overall survival at multiple time points up to 24 months post-treatment, along with acute and longer-term treatment toxicities and tumor responses over two years. Patient-reported health and tumor-specific quality of life are also measured up to 24 months, providing comprehensive insight into treatment impact and safety.

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study